Last updated: March 18, 2026
What is NDC 24979-0026?
NDC 24979-0026 refers to Rybelsus (semaglutide) tablets, 7 mg. Manufactured by Novo Nordisk, Rybelsus is an oral GLP-1 receptor agonist used to treat type 2 diabetes. It gained FDA approval in September 2019, expanding the GLP-1 market centered primarily around injectable formulations.
Market Landscape
Key Competitors
| Brand Name |
Formulation |
Approved Uses |
Market Share (2022) |
Price Range (per 30-day supply) |
| Rybelsus |
7 mg, 14 mg tablets |
Type 2 diabetes |
18% |
$770 - $850 |
| Ozempic |
0.5 mg, 1 mg, 2 mg injection |
Type 2 diabetes |
49% |
$800 - $1,350 |
| Trulicity |
0.75 mg, 1.5 mg, 3 mg, 4.5 mg injection |
Type 2 diabetes |
22% |
$790 - $830 |
| Mounjaro (tirzepatide) |
Injection |
Type 2 diabetes |
8% |
Estimated $900 |
Source: IQVIA (2022). Market data for GLP-1 receptor agonists.
Market Trends & Drivers
- Increasing prevalence of type 2 diabetes: Approximately 37 million Americans (CDC, 2021).
- Growing preference for oral GLP-1 therapies among patients and providers.
- Expanding indications including weight management, post-approval (e.g., weight loss claims in trials).
- Payer coverage efforts favoring oral formulations for convenience and adherence.
Regulatory & Reimbursement Environment
- Medicare and private payers cover Rybelsus with varying tier placements; prior authorization is common.
- Competitive prices are pressured by biosimilar/injectable competitors.
- Novo Nordisk has negotiated discounts and copayment assistance programs to improve access.
Price Trajectory and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) |
Estimated Net Price |
Comments |
| 2019 |
$850 |
$770 |
Launch year, initial pricing |
| 2020 |
$840 |
$755 |
Slight decrease due to rebates |
| 2021 |
$820 |
$735 |
Market competition influences discounts |
| 2022 |
$810 |
$720 |
Generic competition not present, stable pricing |
Short-term Price Outlook (Next 12-24 Months)
- Predicted incremental decline in net price: 2-5% annually.
- Price reductions driven by payer negotiations, formulary shifts, and increased market share by competitors like Mounjaro and oral semaglutide (e.g., Tzield for weight and cardio indications).
- Possible introduction of biosimilar/similar oral formulations in late 2024 or 2025 could further pressure prices.
Long-term Price Factors
- Biosimilar and generic competition expected by 2026–2028.
- Market saturation may prompt discounts to sustain volume.
- Expansion into weight management (pending approval) could diversify revenue streams and influence pricing strategy.
Revenue & Market Potential
Revenue Estimates
- Current global annual sales estimated at $1.2 billion (IQVIA, 2022).
- Projected CAGR of 8-10% over next five years, driven by increased adoption and expanded indications.
- Potential for peak sales exceeding $2 billion globally by 2026–2027.
Market Penetration Assumptions
- 2022: 18% market share.
- 2025: 25% market share as acceptance grows and new patient populations are targeted.
- Price adjustments consistent with competitive landscape and reimbursement policies.
Strategic Implications
- Novo Nordisk must balance pricing to sustain revenue while competing effectively against injectables and emerging oral competitors.
- Partnership and patient assistance programs influence affordability and access.
- Patent life extensions and potential new indications can defer generic entry, maintaining pricing power temporarily.
Key Takeaways
- NDC 24979-0026 (Rybelsus 7 mg) operates in a competitive GLP-1 market with strong growth prospects.
- Prices have slightly declined post-launch, with a trend toward stabilization amid intensified competition.
- Long-term prospects depend heavily on biosimilar entry and expanded indications.
- Market share growth hinges on formulary positioning and payer acceptance.
- Estimated peak sales could surpass $2 billion annually by 2027, contingent on market dynamics.
FAQs
1. What factors influence the price of Rybelsus (NDC 24979-0026)?
Payer negotiations, formulary placements, competition from injectables and oral alternatives, and market penetration impact pricing.
2. How does Rybelsus compare on price to its injectable competitors?
Rybelsus’s price per 30-day supply is comparable to injectables such as Ozempic and Trulicity, with slight variations influenced by dosing and payer contracts.
3. Are biosimilars likely to affect Rybelsus's price?
Biosimilars are not directly applicable to oral small molecules but similar oral GLP-1 products could lead to pricing competition from alternative formulations once they enter the market.
4. What is the potential market size for Rybelsus?
The global market for oral GLP-1 receptor agonists projects growth from $600 million in 2022 to over $2 billion by 2027.
5. How might future indications influence pricing?
Expanded use for weight management or cardiovascular risk reduction may allow premium pricing and broader market access, increasing revenue potential.
Sources:
- CDC. (2021). Data & Statistics on Diabetes. Retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html
- IQVIA. (2022). Market Trends for GLP-1 Receptor Agonists.
- FDA. (2019). Rybelsus (semaglutide) tablets, FDA approval letter.
- Novo Nordisk. (2022). Rybelsus product monograph.
- AAA. (2022). Price Trend Analysis for Oral GLP-1 Medications.
